We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You may need to tell DVLA if you have lung cancer - download the correct form if you need to let them know
You may need to tell DVLA if you have cancer - if you do, download the correct form to let them know
Quarterly updates to the emergency presentations of cancer data by Public Health England.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
This document sets out the NHS Bowel Cancer Screening Programme's (BCSP) pathology guidelines for reporting lesions.
This document sets out for the programme specific operating model (PSOM) for quality assurance of the NHS Bowel Cancer Screening Programme.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Information on the computed tomography colonography (CTC) scan for people who need further investigations following their NHS bowel cancer screening.
Information and sources of further guidance relating to the current shortage of products used in the treatment of some bladder cancers
Estimated proportion of all malignant cancers where patients first presented as an emergency.
Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.
A statement from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
One-year cancer survival by Clinical Commissioning Group for all-cancers combined, 3 cancers combined, breast, colorectal and lung.
This is the council’s note about renal cancer and occupational exposure to trichloroethylene (TCE).
One-year cancer survival by Clinical Commissioning Group (CCG) for all cancers combined – breast, colorectal and lung.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.